Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Related topics
Recorded webinar: Anesthesia Considerations in Small Animal Imaging
Mar 13, 2023
Anesthesia settings and operation of Optical Imaging Systems: methods, animal handling, safety and regulatory...
Introducing Cytek Human Leukocyte Kit, the first ever 15-color lyse no-wash assay
Mar 13, 2023
This kit has been designed to enumerate all major leukocyte subsets and it mirrors and expands on those identified in a...
Immunofluorescence Imaging for Rare Cell Detection with CyteFinder II
Mar 7, 2023
CyteFinder II Instruments are high speed, whole slide imaging systems with options for liquid biopsy analysis and...
NanoCellect Webinar: Optimizing the Cell Line Development Process with Microfluidic Cell Sorting
Mar 3, 2023
Single-cell selection and cloning are required for bioengineering workflows such as antibody production, cell therapy,...
Flash news - did you know, that you can use Singulator S100 also for plant research?
Feb 10, 2023
In this short TechNote you can find how Singulator can help the data quality in Single cell sequencing - now even in...
Webinar: Spatial Biology and immunofluorescence to study human pancreata in in type 1 diabete
Feb 9, 2023
In this webinar, Dr. Quesada-Masachs from La Jolla Institute for Immunology reveals the image analysis pipeline that...
Advances in Leukemia research using shear flow and Bioflux system
Feb 3, 2023
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
Webinar: Dose Reduction and Image Enhancement in Preclinical Mouse Imaging using Deep Learning
Jan 31, 2023
In this webinar, ir. Florence Muller (Ghent University - University of Pennsylvania) is presenting two recent studies...
Advance your Spatial Biology, customize your panel design with RareCyte Orion reagents
Jan 23, 2023
Orion system, the highly multiplexed fluorescent imaging system, in combination with dedicated reagents, empower...
Extensive assessment of Cytokine production on the NovoCyte Advanteon flow cytometer
Jan 13, 2023
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
Jun 22, 2017
Clinical and preclinical non-invasive PET imaging is employed in the development and validation of therapeutic agents for cancer and neurological disorders, and a range of other diseases. Reported studies have used numerous agents including FDG, FLT, FMISO and FAZA as early biomarkers of drug efficacy. Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available. Probably two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. In the article, you can find a brief introduction to preclinical PET imaging for such studies.
Related technologies: PET, SPECT, CT
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com/